Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Invicta DiagnosticNSE:INVICTA +3.88%22 PB Ratio is 1.75 as of Aug. 20, 2026, which is 23% below its 10-year median of 2.26. GuruFocus rates NSE:INVICTA with a GF Score™ of 22/100. The stock has 3 warning signs investors should review. Among 193 Medical Diagnostics & Research companies, Invicta Diagnostic ranks better than 61.66% on this metric.
The historical rank and industry rank for Invicta Diagnostic's PB Ratio or its related term are showing as below:
NSE:INVICTA'
s PB Ratio Range Over the Past 10 Years
Min: 1.51 Med: 2.26 Max: 7.42
Current: 1.76
During the past 3 years, Invicta Diagnostic's highest PB Ratio was 7.42. The lowest was 1.51. And the median was 2.26.
NSE:INVICTA's PB Ratio is ranked better than 61.66% of 193
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.24
vs NSE:INVICTA: 1.76
During the past 12 months, Invicta Diagnostic's average Book Value Per Share Growth Rate was 241.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Invicta Diagnostic PB Ratio Related Terms
Invicta Diagnostic PB Ratio Historical Data
* Premium members only.
The historical data trend for Invicta Diagnostic's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invicta Diagnostic PB Ratio Chart
Invicta Diagnostic Annual Data
Trend
Mar24
Mar25
Mar26
PB Ratio
0.00
0.00
1.59
Invicta Diagnostic Semi-Annual Data
Mar24
Mar25
Sep25
Mar26
PB Ratio
0.00
0.00
0.00
1.59
NSE:INVICTA vs TMO, DHR, IDXX: PB Ratio Comparison
For the Diagnostics & Research subindustry, Invicta Diagnostic's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invicta Diagnostic PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Invicta Diagnostic's PB Ratio distribution charts can be found below:
* The bar in red indicates where Invicta Diagnostic's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Invicta Diagnostic (NSE:INVICTA) has a PB Ratio of 1.75 as of Aug. 20, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Invicta Diagnostic and its competitors. This is 23% below median its historical median of 2.26. Over the past decade, Invicta Diagnostic's PB Ratio has ranged from 1.51 to 7.42. According to the industry distribution chart, Invicta Diagnostic ranks #74 out of 193 companies in the Medical Diagnostics & Research industry, placing it in the top 38.3%.
Is Invicta Diagnostic's PB Ratio too high?
Invicta Diagnostic's current PB Ratio of 1.75 is 23% below median its 10-year median of 2.26. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 7.42. The Medical Diagnostics & Research industry median PB Ratio is 2.24. Invicta Diagnostic's value of 1.75 is 21.9% below this industry median. Based on the distribution chart, Invicta Diagnostic ranks #74 out of 193 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Invicta Diagnostic has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Invicta Diagnostic's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Invicta Diagnostic ranks #74 out of 193 companies for PB Ratio. This puts Invicta Diagnostic in the upper half of its industry. The industry median PB Ratio is 2.24. Invicta Diagnostic's value of 1.75 is 21.9% below this benchmark. Historically, Invicta Diagnostic's own PB Ratio has ranged from 1.51 to 7.42 over the past decade. While the company's 10-year median is 2.26 vs. the industry median of 2.24, Invicta Diagnostic has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.24, based on 193 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Invicta Diagnostic's current PB Ratio of 1.75 is 21.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Invicta Diagnostic and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invicta Diagnostic's current PB Ratio is 1.75, which is 23% below median its own 10-year median of 2.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invicta Diagnostic stock overvalued right now?
Invicta Diagnostic (NSE:INVICTA) has a current PB Ratio of 1.75. The current PB Ratio is 1.75, which is 23% below median its 10-year median of 2.26 and 21.9% below the Medical Diagnostics & Research industry median of 2.24. Invicta Diagnostic's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Invicta Diagnostic (NSE:INVICTA), the current PB Ratio is 1.75 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invicta Diagnostic Ltd is engaged in the business of medical and diagnostic services and operates diagnostic centres providing medical testing and allied healthcare services in the Mumbai Metropolitan Region. The Company runs a diagnostic chain comprising seven diagnostic centres and one centralised laboratory across MMR in Maharashtra and operates under a hub and spoke model with a flagship hub in Thane, additional hub centres, spoke centres, and a centralised laboratory. Its service offerings include radiology and imaging, pathology and clinical laboratory tests, teleradiology, and services such as ultrasound, X Ray, CT scan, MRI scan, PET scan, and cardiac diagnostics, with patient convenience supported through home sample collection, house calls, and multiple report delivery options.
22GF Score
Get the complete analysis for NSE:INVICTA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INVICTA has been successfully added to your 
